tbuckley/cabot-search huggingface dataset:
Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma
Authors: Min Wang, Shutao Pan, Tingting Qin, Xiaowu Xu, Xiaobing Huang, Jun Liu, Xuemin Chen, Wenxing Zhao, Jingdong Li, Chen Liu, Dewei Li, Jianhua Liu, Yahui Liu, Baoyong Zhou, Feng Zhu, Shunrong Ji, He Cheng, Zheng Li, Jing Li, Yichen Tang, Xuehui Peng, Guangsheng Yu, Weibo Chen, Hongqin Ma, Yongfu Xiong, Lingyu Meng, Pei Lu, Zhenxiong Zhang, Xianjun Yu, Hang Zhang, Renyi Qin
Journal: JAMA Surgery (2023)

The safety and efficacy of laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma remain controversial.
Perceived Implications of Compensation Structure for Academic Surgical Practice
Authors: Caitlin B. Finn, Solomiya Syvyk, Regan W. Bergmark, Heather L. Yeo, Jennifer F. Waljee, Elizabeth C. Wick, Rachel R. Kelz
Journal: JAMA Surgery (2023)

This qualitative study examines how incentive-based and salary-only compensation models affect academic surgeons.
Metformin Cessation and Dementia Incidence
Authors: Scott C. Zimmerman, Erin L. Ferguson, Vidhu Choudhary, Dilrini K. Ranatunga, Akinyemi Oni-Orisan, Eleanor Hayes-Larson, Aline Duarte Folle, Elizabeth Rose Mayeda, Rachel A. Whitmer, Paola Gilsanz, Melinda C. Power, Catherine Schaefer, M. Maria Glymour, Sarah F. Ackley
Journal: JAMA Network Open (2023)

Prior studies suggested that metformin may be associated with reduced dementia incidence, but associations may be confounded by disease severity and prescribing trends. Cessation of metformin therapy in people with diabetes typically occurs due to signs of kidney dysfunction but sometimes is due to less serious adverse effects associated with metformin.
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials
Authors: Laura Fertitta, Christina Bergqvist, Kavita Y Sarin, Scott R Plotkin, Christopher Moertel, Andrea K Petersen, Ashley Cannon, Yemima Berman, Dominique C Pichard, Class Röhl, Andres Lessing, Bernadette Brizion, Bastien Peiffer, Philippe Ravaud, Viet-Thi Tran, Marie-Laure Armand, Sabine Moryousef, Salah Ferkal, Arnaud Jannic, Khaled Ezzedine, Pierre Wolkenstein, Sarah Adsit, Shivani Ahlawat, Krizelle Alcantara, Rosemary Anderson, Kara Anstett, Lisa Aouad, Rob Avery, Carolina Barnett-Tapia, Belinda Barton, Catherine Batlle, David Bedwell, Tammy Benson O'Brian, Dale Berg, Christina Bergqvist, Yemima Berman, Chetan Bettegowda, Jaishri Blakeley, Rob Brainin, Sara Brebbia Dirksen, Frank Buono, Susan Buono, Wenli Cai, Cynthia Campen, Ashley Cannon, Kelly Carpenter, Alexandra Cellucci, Nicolas Champollion, Long-Shen Chang, Peter de Blank, Allison del Castillo, Laura Didier, Eva Dombi, Gregg Erickson, Gareth Evans, Khaled Ezzedine, Onno Faber, Laura Fertitta, Michael Fisher, Barbara Franklin, Edith Garrett, Madalyn Gibson-Williams, Marco Giovannini, Dani Glad, Deborah Gold, Adam Goodkind, Kayo Goto, Jane Grabowski, Vito Grasso, Andrea Gross, Lorenza Grotti, David Gutmann, Diana Haberkamp, Kristine Haebich, Cindy Hahn, Oliver Hanemann, Cynthia Hingtgen, Matt Hocking, Eric Hunt, Maureen Hussey, Kelly Janke, Jennifer Janusz, Justin Jordan, Valerie Kaer, Matthias Karajannis, Kim Keeling, Bob Kesterson, Aerang Kim, Hannah Kim, Yoori Kim, Bonnie Klein-Tasman, Laura Klesse, Kimberley Koetsier, Edina Komlodi-Pasztor, Noelle Larson, Andre Leier, Erica Leif, Andres Lessing, Robert Listernick, Elana Loftspring, Sharon Loftspring, K Ina Ly, Linda Manth, Staci Martin, Sherri McKnight, Miranda McManus, Vanessa Merker, Elizabeth Morehouse, Irene Moss, Lara Mukabenov, Patricia Newman, Beverly Oberlander, Jonathan Payne, Drea Peterson, Dominque Pichard, Rene Pierpoint, Scott Plotkin, Dorothy Pope, Linda Popplewell, Natalie Pride, Marcus Ratley, Steven Rhodes, Jonathan Rios, Inka Ristow, Bill Riter, Claas Rohl, Carlos Romo, Adam Rosenberg, Tena Rosser, Jessica Samblanet, Kavita Sarin, Herb Sarnoff, Natalie Schneider, Elizabeth Schorry, Mary Sell, Steven Sheard, Dani Silverman, Brittany Simpson, Melissa Smith, Connie Sorman, Verena Staedtke, Pete Stavinoha, Anat Stemmer-Rachamimov, David Stevenson, Taylor Sundby, Heather Thompson, Nicole Ullrich, Meena Upadhyaya, Marjan van de Vrie, Dave Viskochil, Jeremie Vitte, James Walker, Jo Wallace, Deann Wallis, Karin Walsh, Shannon Weaver, Hannah Weisman, Bradley Welling, Brigitte Widemann, Tracy Wirtanen, Pierre Wolkenstein, Pamela Wolters, Mary Achtziger Wong, Jiangbing Zhou
Journal: British Journal of Dermatology (2023)

Cutaneous neurofibromas (cNF) are considered one of the highest burdens of neurofibromatosis type 1 (NF1). To date, no medical treatment can cure cNF or prevent their development. In that context, there is an urgent need to prepare and standardize the methodology of future trials targeting cNF.
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Zilu Wang, Matteo Burigotto, Sabrina Ghetti, François Vaillant, Tao Tan, Bianca D. Capaldo, Michelle Palmieri, Yumiko Hirokawa, Lin Tai, Daniel S. Simpson, Catherine Chang, Allan Shuai Huang, Elizabeth Lieschke, Sarah T. Diepstraten, Deeksha Kaloni, Chris Riffkin, David C.S. Huang, Connie S.N. Li Wai Suen, Alexandra L. Garnham, Peter Gibbs, Jane E. Visvader, Oliver M. Sieber, Marco J. Herold, Luca L. Fava, Gemma L. Kelly, Andreas Strasser
Journal: Cancer Discovery (2023)

Abstract Mutations in the tumor suppressor TP53 cause cancer and impart poor chemotherapeutic responses, reportedly through loss-of-function, dominant-negative effects and gain-of-function (GOF) activities. The relative contributions of these attributes is unknown. We found that removal of 12 different TP53 mutants with reported GOFs by CRISPR/Cas9 did not impact proliferation and response to chemotherapeutics of 15 human cancer cell lines and colon cancer–derived organoids in culture. Moreover, removal of mutant TP53/TRP53 did not impair growth or metastasis of human cancers in immune-deficient mice or growth of murine cancers in immune-competent mice. DepMap mining revealed that removal of 158 different TP53 mutants had no impact on the growth of 391 human cancer cell lines. In contrast, CRISPR-mediated restoration of wild-type TP53 extinguished the growth of human cancer cells in vitro. These findings demonstrate that LOF but not GOF effects of mutant TP53/TRP53 are critical to sustain expansion of many tumor types. Significance: This study provides evidence that removal of mutant TP53, thereby deleting its reported GOF activities, does not impact the survival, proliferation, metastasis, or chemotherapy responses of cancer cells. Thus, approaches that abrogate expression of mutant TP53 or target its reported GOF activities are unlikely to exert therapeutic impact in cancer. See related commentary by Lane, p. 211 . This article is featured in Selected Articles from This Issue, p. 201
Effectiveness of Surgeon-Performed Paravertebral Block Analgesia for Minimally Invasive Thoracic Surgery
Authors: Josephine Chenesseau, Alex Fourdrain, Bruno Pastene, Aude Charvet, Adrien Rivory, Karine Baumstarck, Ilies Bouabdallah, Delphine Trousse, David Boulate, Geoffrey Brioude, Lucile Gust, Matthieu Vasse, Cesare Braggio, Pierre Mora, Ambroise Labarriere, Laurent Zieleskiewicz, Marc Leone, Pascal Alexandre Thomas, Xavier-Benoit D’Journo
Journal: JAMA Surgery (2023)

In minimally invasive thoracic surgery, paravertebral block (PVB) using ultrasound (US)-guided technique is an efficient postoperative analgesia. However, it is an operator-dependent process depending on experience and local resources. Because pain-control failure is highly detrimental, surgeons may consider other locoregional analgesic options.
Antiplatelet Therapy in Patients With Abdominal Aortic Aneurysm Without Symptomatic Atherosclerotic Disease
Authors: Chalotte W. Nicolajsen, Mette Søgaard, Martin Jensen, Nikolaj Eldrup, Torben B. Larsen, Samuel Z. Goldhaber, Christian-Alexander Behrendt, Peter B. Nielsen
Journal: JAMA Network Open (2023)

Patients with abdominal aortic aneurysm have a high risk of ischemic events associated with concomitant atherosclerotic cardiovascular disease, and current clinical practice guidelines recommend antiplatelet therapy to mitigate this risk. However, in patients with aneurysms without symptomatic atherosclerosis, the benefit of antiplatelet therapy has been sparsely investigated.To estimate the effect of antiplatelets on the risk of ischemic events and bleeding in individuals with abdominal aneurysms with no symptomatic atherosclerotic vascular disease.A comparative effectiveness research study using a target trial emulation framework was performed. Population-based, cross-linked observational data from Danish national health registries containing comprehensive, individual-level information on all Danish citizens were used to evaluate patients who were antiplatelet-naive and diagnosed with abdominal aortic aneurysms, with no record of symptomatic atherosclerotic vascular disease, from January 1, 2010, through August 21, 2021.Prescription filled for aspirin or clopidogrel.Risk of ischemic events (myocardial infarction and/or ischemic stroke) and risk of major bleeding. For target trial emulation, trials were emulated as sequential, contingent on patient eligibility at the time of inclusion, and were evaluated by means of pooled logistic regression models to estimate the intention-to-treat and as-treated effects, expressed as hazard ratio (HR) and event-free survival.A total of 6344 patients (65.2% men; age, 72 [IQR, 64-78] years) provided 131 047 trial cases; 3363 of these cases involved initiation of antiplatelet therapy and 127 684 did not. A total of 182 ischemic events occurred among initiators and 5602 ischemic events occurred among noninitiators, corresponding to an intention-to-treat HR of 0.91 (95% CI, 0.73-1.17) and an estimated absolute event-free survival difference of -0.6% (95% CI, -1.7% to 0.5%). After censoring nonadherent person-time, the treatment HR was 0.90 (95% CI, 0.68-1.20), with similar risk difference. For bleeding, the intention-to-treat HR was 1.26 (95% CI, 0.97-1.58) and the event-free survival difference was 1.0%. The treatment HR was 1.21 (95% CI, 0.82-1.72); the risk difference was similar.In this study, no evidence of effectiveness of antiplatelet therapy to lower the risk of ischemic events and a trend toward higher bleeding risk was noted. The observed differences between the treatment groups were minimal, suggesting limited clinical relevance of antiplatelet treatment.
Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
Authors: Katherine Anais Sadaniantz, Jeffrey A. Shih, Lara C. Kovell
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Regulatory Oversight of Cardiovascular Devices—Why We Care
Authors: Clyde W. Yancy, Patrick T. O’Gara, Robert O. Bonow
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Donor Immune Cells May Reduce or Eliminate Need for Immunosuppressants
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Portfolio Diet Score and Risk of Cardiovascular Disease: Findings From 3 Prospective Cohort Studies
Authors: Andrea J. Glenn, Marta Guasch-Ferré, Vasanti S. Malik, Cyril W.C. Kendall, JoAnn E. Manson, Eric B. Rimm, Walter C. Willett, Qi Sun, David J.A. Jenkins, Frank B. Hu, John L. Sievenpiper
Journal: Circulation (2023)

BACKGROUND: The plant-based Portfolio dietary pattern includes recognized cholesterol-lowering foods (ie, plant protein, nuts, viscous fiber, phytosterols, and plant monounsaturated fats) shown to improve several cardiovascular disease (CVD) risk factors in randomized controlled trials. However, there is limited evidence on the role of long-term adherence to the diet and CVD risk. The primary objective was to examine the relationship between the Portfolio Diet Score (PDS) and the risk of total CVD, coronary heart disease (CHD), and stroke. METHODS: We prospectively followed 73 924 women in the Nurses’ Health Study (1984–2016), 92 346 women in the Nurses’ Health Study II (1991–2017), and 43 970 men in the Health Professionals Follow-up Study (1986–2016) without CVD or cancer at baseline. Diet was assessed using validated food frequency questionnaires at baseline and every 4 years using a PDS that positively ranks plant protein (legumes), nuts and seeds, viscous fiber sources, phytosterols (mg/day), and plant monounsaturated fat sources, and negatively ranks foods high in saturated fat and cholesterol. RESULTS: During up to 30 years of follow-up, 16 917 incident CVD cases, including 10 666 CHD cases and 6473 strokes, were documented. After multivariable adjustment for lifestyle factors and a modified Alternate Healthy Eating Index (excluding overlapping components), comparing the highest with the lowest quintile, participants with a higher PDS had a lower risk of total CVD (pooled hazard ratio [HR], 0.86 [95% CI, 0.81–0.92]; P trend &lt;0.001), CHD (pooled HR, 0.86 [95% CI, 0.80–0.93]; P trend =0.0001), and stroke (pooled HR, 0.86 [95% CI, 0.78–0.95]; P trend =0.0003). In addition, a 25-percentile higher PDS was associated with a lower risk of total CVD (pooled HR, 0.92 [95% CI, 0.89–0.95]), CHD (pooled HR, 0.92 [95% CI, 0.88–0.95]), and stroke (pooled HR, 0.92 [95% CI, 0.87–0.96]). Results remained consistent across sensitivity and most subgroup analyses, and there was no evidence of departure from linearity for CVD, CHD, or stroke. In a subset of participants, a higher PDS was associated with a more favorable blood lipid and inflammatory profile. CONCLUSIONS: The PDS was associated with a lower risk of CVD, including CHD and stroke, and a more favorable blood lipid and inflammatory profile, in 3 large prospective cohorts.
Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival
Authors: Marla Lipsyc-Sharf, Karla V. Ballman, Jordan D. Campbell, Hyman B. Muss, Edith A. Perez, Lawrence N. Shulman, Lisa A. Carey, Ann H. Partridge, Erica T. Warner
Journal: JAMA Network Open (2023)

Black women in the United States have higher breast cancer (BC) mortality rates than White women. The combined role of multiple factors, including body mass index (BMI), age, and tumor subtype, remains unclear.To assess the association of race and ethnicity with survival among clinical trial participants with early-stage BC (eBC) according to tumor subtype, age, and BMI.This cohort study analyzed survival data, as of November 12, 2021, from participants enrolled between 1997 and 2010 in 4 randomized adjuvant chemotherapy trials: Cancer and Leukemia Group B (CALGB) 9741, 49907, and 40101 as well as North Central Cancer Treatment Group (NCCTG) N9831, legacy groups of the Alliance of Clinical Trials in Oncology. Median follow-up was 9.8 years.Non-Hispanic Black and Hispanic participants were compared with non-Hispanic White participants within subgroups of subtype (hormone receptor positive [HR+]/ERBB2 [formerly HER2] negative [ERBB2-], ERBB2+, and HR-/ERBB2-), age (<50, 50 to <65, and ≥65 years), and BMI (<18.5, 18.5 to <25.0, 25.0 to <30.0, and ≥30.0).Recurrence-free survival (RFS) and overall survival (OS).Of 9479 participants, 436 (4.4%) were Hispanic, 871 (8.8%) non-Hispanic Black, and 7889 (79.5%) non-Hispanic White. The median (range) age was 52 (19.0-89.7) years. Among participants with HR+/ERBB2- tumors, non-Hispanic Black individuals had worse RFS (hazard ratio [HR], 1.49; 95% CI, 1.04-2.12; 5-year RFS, 88.5% vs 93.2%) than non-Hispanic White individuals, although the global test for association of race and ethnicity with RFS was not significant within any tumor subtype. There were no OS differences by race and ethnicity in any subtype. Race and ethnicity were associated with OS in young participants (age <50 years; global P = .008); young non-Hispanic Black participants (HR, 1.34; 95% CI, 1.04-1.71; 5-year OS, 86.6% vs 92.0%) and Hispanic participants (HR, 1.62; 95% CI, 1.16-2.29; 5-year OS, 86.2% vs 92.0%) had worse OS than young non-Hispanic White participants. Race and ethnicity were associated with RFS in participants with BMIs of 25 to less than 30, with non-Hispanic Black participants having worse RFS (HR, 1.81; 95% CI, 1.23-2.68; 5-year RFS, 83.2% vs 87.3%) than non-Hispanic White participants.In this cohort study, racial and ethnic survival disparities were identified in patients with eBC receiving standardized initial care, and potentially at-risk subgroups, for whom focused interventions may improve outcomes, were found.
The Delineation of Another Standard for Postoperative Pain Management Following Thoracic Surgery
Authors: Hailey Theeuwen, Anthony W. Kim
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal